TuHURA Biosciences, Inc. (HURA)
1.63
+0.02
(+1.24%)
USD |
NASDAQ |
Nov 06, 16:00
1.66
+0.03
(+1.84%)
After-Hours: 05:08
TuHURA Biosciences Enterprise Value : 107.09M for Nov. 6, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| November 06, 2026 | 107.09M |
| November 05, 2026 | 105.82M |
| November 04, 2026 | 112.82M |
| November 03, 2026 | 108.68M |
| November 02, 2026 | 112.82M |
| October 30, 2026 | 126.20M |
| October 29, 2026 | 134.48M |
| October 28, 2026 | 130.02M |
| October 27, 2026 | 137.66M |
| October 26, 2026 | 133.20M |
| October 23, 2026 | 142.12M |
| October 22, 2026 | 131.29M |
| October 21, 2026 | 136.07M |
| October 20, 2026 | 115.37M |
| October 19, 2026 | 116.64M |
| October 16, 2026 | 115.37M |
| October 15, 2026 | 119.83M |
| October 14, 2026 | 115.37M |
| October 13, 2026 | 118.55M |
| October 12, 2026 | 124.29M |
| October 09, 2026 | 128.11M |
| October 08, 2026 | 126.20M |
| October 07, 2026 | 129.38M |
| October 06, 2026 | 127.47M |
| October 05, 2026 | 122.38M |
| Date | Value |
|---|---|
| October 02, 2026 | 124.92M |
| October 01, 2026 | 129.38M |
| September 30, 2026 | 137.02M |
| September 29, 2026 | 135.11M |
| September 28, 2026 | 136.39M |
| September 25, 2026 | 137.02M |
| September 24, 2026 | 137.02M |
| September 23, 2026 | 133.84M |
| September 22, 2026 | 138.93M |
| September 21, 2026 | 142.12M |
| September 18, 2026 | 137.02M |
| September 17, 2026 | 136.39M |
| September 16, 2026 | 132.56M |
| September 15, 2026 | 132.56M |
| September 14, 2026 | 133.84M |
| September 11, 2026 | 133.84M |
| September 10, 2026 | 132.56M |
| September 09, 2026 | 131.29M |
| September 08, 2026 | 138.30M |
| September 04, 2026 | 139.57M |
| September 03, 2026 | 137.02M |
| September 02, 2026 | 136.39M |
| September 01, 2026 | 132.56M |
| August 31, 2026 | 138.93M |
| August 28, 2026 | 137.66M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| ACADIA Pharmaceuticals, Inc. | 2.764B |
| Alnylam Pharmaceuticals, Inc. | 20.29B |
| Anika Therapeutics, Inc. | 176.07M |
| Savara, Inc. | 849.45M |
| Vericel Corp. | 2.710B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -9.223M |
| Total Expenses (Quarterly) | 9.223M |
| EPS Diluted (Quarterly) | -0.1442 |
| Earnings Yield | -32.72% |
| Normalized Earnings Yield | -34.33 |